NASDAQ:INVAInnoviva Stock Price, Forecast & News

Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INVA shares have increased by 14.6% and is now trading at $13.80. View which stocks have been most impacted by Coronavirus.

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Innoviva.

Innoviva Inc (NASDAQ:INVA) issued its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.36 by $0.23. The biotechnology company earned $78.68 million during the quarter. Innoviva had a return on equity of 59.11% and a net margin of 66.50%. View Innoviva's earnings history.

News stories about INVA stock have trended negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Innoviva earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Innoviva.

Innoviva saw a increase in short interest in June. As of June 15th, there was short interest totaling 12,650,000 shares, an increase of 7.0% from the May 31st total of 11,820,000 shares. Based on an average daily volume of 830,900 shares, the days-to-cover ratio is currently 15.2 days. Currently, 18.4% of the shares of the company are short sold. View Innoviva's Current Options Chain.

Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Micron Technology (MU), Pfizer (PFE), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Occidental Petroleum (OXY) and Progenics Pharmaceuticals (PGNX).

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $13.80.

Innoviva has a market capitalization of $1.40 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.

The official website for Innoviva is www.inva.com.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]